The objective of this contract is to acquire pharmacologic and toxicologic data on new drugs for the treatment of Cancer and the Acquired Immunodeficiency Syndrome (AIDS) and AIDS-related illnesses. The data will be included in an Investigational New Drug (IND) application to the FDA which is required prior to the initiation of human clinical trials. Level A contract is 46,875 hours over 5 years. Level B contract is 93,750 hours over 5 years. This contract will be awarded at Level A because the laboratory has the capability, expertise and experience to do the amount of work required.
| Horn, Thomas L; Harder, J Brooks; Johnson, William D et al. (2008) Integration of in vivo and in vitro approaches to characterize the toxicity of Antalarmin, a corticotropin-releasing hormone receptor antagonist. Toxicology 248:8-17 |
| Glaze, Elizabeth R; Lambert, Amy L; Smith, Adaline C et al. (2005) Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance. Cancer Chemother Pharmacol 56:637-47 |
